Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200-Day Moving Average – What’s Next?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.77 and traded as high as $3.78. Sonoma Pharmaceuticals shares last traded at $3.65, with a volume of 38,648 shares trading hands.

Wall Street Analyst Weigh In

SNOA has been the topic of a number of research analyst reports. Wall Street Zen upgraded Sonoma Pharmaceuticals to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Price Performance

The stock has a fifty day moving average of $3.55 and a 200 day moving average of $3.78. The stock has a market cap of $6.21 million, a price-to-earnings ratio of -1.67 and a beta of 1.61.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.18. Sonoma Pharmaceuticals had a negative net margin of 20.57% and a negative return on equity of 45.46%. As a group, equities analysts expect that Sonoma Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management bought a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned about 2.06% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.